2024年9月10-12日·無錫·2024第三屆生物偶聯(lián)藥全球創(chuàng)新峰會

10月前發(fā)布在 活動會議

2024年9月10-12日·無錫·2024第三屆生物偶聯(lián)藥全球創(chuàng)新峰會-肽度TIMEDOO

由藥明合聯(lián)WuXi XDC和佰傲谷BioValley共同主辦的2024第三屆生物偶聯(lián)藥全球創(chuàng)新峰會（Global XDC 2024），將于9月10-12日在無錫重磅回歸。大會涵蓋2個主論壇+4個分論壇，預(yù)計參會企業(yè)300+家，參會專家100+位，參會觀眾1000+人。大會以“探索偶聯(lián)藥的無限可能”為主題，將聚焦于新靶點發(fā)現(xiàn)與驗證、ADC和新型偶聯(lián)藥物創(chuàng)新技術(shù)、載荷-連接子新技術(shù)，以及CMC挑戰(zhàn)和商業(yè)化策略等內(nèi)容，探索前沿技術(shù)進(jìn)步、分享國際優(yōu)秀生物科技公司的創(chuàng)新經(jīng)驗、引領(lǐng)ADC和XDC的新未來！

本屆峰會邀請了眾多生物偶聯(lián)藥領(lǐng)域的國際專家與會，共同探討創(chuàng)新合作，碰撞思想，助力生物偶聯(lián)藥行業(yè)蓬勃發(fā)展。

1.國際嘉賓陣容來襲，聆聽偶聯(lián)藥的世界聲音

2024年9月10-12日·無錫·2024第三屆生物偶聯(lián)藥全球創(chuàng)新峰會-肽度TIMEDOO

2.精選熱門議題一覽，探索偶聯(lián)藥的無限可能

2024年9月10-12日·無錫·2024第三屆生物偶聯(lián)藥全球創(chuàng)新峰會-肽度TIMEDOO

Keynote Speech

Rina-S-the missing link(er)
Protein homeostasis by dual-precision targeted protein degradation and stabilization
A novel dual-payload ADC platform to overcome payload resistance and maximize therapeutic promise of ADCs
MYTX-011: a cMET-targeting ADC engineered for anti-tumor activity against a broader spectrum of cMET expression
NTX1105: development of a best-in-class ADC targeting Nectin-4
Collaborating within the global life science ecosystem to advance breakthrough science

論壇一：Next generation ADCs: Novel targets, payloads, payload-linkers, and conjugation technologies

Next generation ADCs: novel targets, payloads, linkers and conjugation technologies
Nexatecan?: OHPAS-able Topo1 inhibitor for ADC
Introduction to PINOT-ADC platform: novel Top1 inhibitor payload, tandem cleavable and super-hydrophilic linker, ? and dual payload system
Versatile drug bundle-based ADC platform: achieving site-specific conjugation, DAR of 8 or 12, and dual payloads
CS5001, a potential best-in-class ROR1 ADC
Discovery of AT65474, a highly selective anti-CLDN6 ADC with a proprietary payload
Polysorbates in biopharmaceuticals-approaches to mitigate risk

論壇二：Bioconjugates development beyond ADCs

RDC-the exploration of new drug modality in unmet clinical need
Intra-cellular mutant epitopes-novel targets for ADC and bispecific antibodies?
GBB’s AI-enabled ecosystem elevating biological drug development
Developing radiopharmaceuticals targeting CLDN 18.2 with nanobodies
Fully human common light chain technology for novel ADCs

論壇三：Innovative bioconjugate discovery: from target selection to PreClinical Candidate (PCC)

Harnessing AbClick Pro^?for AT-211: leading CLDN 18.2 ADCs with superior therapeutic index
An overview on the new topoisomerases inhibitors technologies
Next generation ADCs:novel targets, payloads, linkers and conjugation technologies
Challenges and solutions for clinical PK bioanalysis of antibody drug conjugates (ADCs)

論壇四：CMC challenges and commercialization strategies

CMC scale-up challenges and COGs for site specific ADCs
Innovative bioassays: translate clinical effects into a rigorous system of XDC product assessment
The integrated analytical platform enables accelerated CMC development of XDCs
QbD considerations for ADC process
How WuXiBio’s Microbial Platform facilitates rapid and cost-effective ADC development and manufacturing
Non-clinical strategies for ADC drugs